{'fraction_non_alphanumeric': 0.032818532818532815, 'fraction_numerical': 0.05019305019305019, 'mean_word_length': 5.4875, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lipid‐lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic

We documented temporal changes in the use of lipid‐lowering medications and achievement of cholesterol targets in an Australian diabetes clinic. The number of patients using lipid‐lowering therapy for primary or secondary cardiovascular prevention increased from 6 to 69% between 1993–1995 and 2014–2016, which corresponded to a decrease in low‐density lipoprotein cholesterol levels from 3.7 to 2.4 mmol/L (P < 0.01).